cardiovascular disease Archives - CRS. Experts. Early Phase.

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.

Science 25. Januar 2023

Read Article

Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.

Science 21. November 2022

First published in Expert Opinion on Pharmacotherapy on 2013 Nov. Expert Opin Pharmacother. 2013 Nov;14(16):2281-96. doi: 10.1517/14656566.2013.838559. Epub 2013 Oct...

Read Article

Glycemic control and cardiovascular benefit: What do we know today?

Science 10. November 2022

ShareTwitter FacebookXingLinkedin

First published in Deutsche Medizinische Wochenschrift on 2010 Feb.Dtsch Med Wochenschr. 2010 Feb;135(7):301-7. doi: 10.1055/s-0029-1244853. Authors: Hanefeld M, Schönauer M,...

Read Article

Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study.

Science 10. November 2022

ShareTwitter FacebookXingLinkedin

First published in Diabetes and Vascular Disease Research on 2010 Apr.Diab Vasc Dis Res. 2010 Apr;7(2):145-50. doi: 10.1177/1479164109358241. Authors: Schöndorf...

Read Article

High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone.

Science 10. November 2022

ShareTwitter FacebookXingLinkedin

First published in Journal of Diabetes Science and Technology on 2010 May.J Diabetes Sci Technol. 2010 May 1;4(3):706-16 Authors: Pfützner...

Read Article

Laboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation.

Science 10. November 2022

ShareTwitter FacebookXingLinkedin

First published in Journal of Diabetes Science and Technology on 2010 May.J Diabetes Sci Technol. 2010 May 1;4(3):717-22 Authors: Siebenhaar...

Read Article

Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.

Science 10. November 2022

ShareTwitter FacebookXingLinkedin

First published in Journal of Diabetes Science and Technology on 2011 May.J Diabetes Sci Technol. 2011 May 1;5(3):784-93 Authors: Pfützner...

Read Article

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.

Science 10. November 2022

ShareTwitter FacebookXingLinkedin

First published in BMC on 2011 Jul.Cardiovasc Diabetol. 2011 Jul 14;10:65. doi: 10.1186/1475-2840-10-65 Authors: Hanefeld M, Pfützner A, Forst T,...

Read Article

Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.

Science 10. November 2022

ShareTwitter FacebookXingLinkedin

First published in Journal of Diabetes Science and Technology on 2011 Jul.J Diabetes Sci Technol. 2011 Jul 1;5(4):989-98 Authors: Pfützner...

Read Article

Cardiovascular benefits of GLP-1-based therapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

Science 9. November 2022

ShareTwitter FacebookXingLinkedin

First published in Experimental Diabetes Research on 2012Exp Diabetes Res. 2012;2012:635472. doi: 10.1155/2012/635472. Authors: Forst T, Weber MM, Pfützner A...

Read Article